GRADE随机对照试验参与者基线特征及其与NHANES队列比较
GRADE是一项在二甲双胍单药治疗基础上比较四种降糖药添加疗效的随机对照试验,纳入5047例2型糖尿病患者,平均年龄57.2岁,HbA1c 7.5%,BMI 34.3 kg/m²,糖尿病病程4.2年,二甲双胍剂量1944 mg/天。按GRADE入选标准筛选NHANES数据,显示该队列可代表二甲双胍单药治疗需加用第二种降糖药的2型糖尿病人群。
要点
- GRADE纳入二甲双胍单药治疗、HbA1c 6.8-8.5%的2型糖尿病患者,随机加用四种降糖药之一。
- 基线平均HbA1c 7.5%,BMI 34.3 kg/m²,糖尿病病程4.2年,二甲双胍剂量1944 mg/天。
- GRADE队列特征与NHANES中符合标准的人群相似,具有代表性。
核心结论
- GRADE队列代表二甲双胍单药治疗需加用第二种降糖药的2型糖尿病人群,将指导四种降糖药添加治疗的临床决策。
研究设计与样本
- GRADE为36中心、非盲、平行治疗组随机对照试验,评估二甲双胍基础上加用四种降糖药的疗效。
- 共纳入5047例2型糖尿病患者,随机分配至格列美脲、西格列汀、利拉鲁肽或甘精胰岛素组。
- 入选标准:诊断年龄≥30岁,糖尿病病程<10年,HbA1c 6.8-8.5%(51-69 mmol/mol),二甲双胍单药治疗。
- 将GRADE入选标准应用于NHANES队列,比较人群特征。
主要发现
- GRADE参与者基线平均年龄57.2±10.0岁,男性占63.6%,白人65.7%,非裔美国人19.8%,亚裔3.6%,美洲原住民2.7%,其他/未知7.6%,西班牙裔/拉丁裔18.4%。
- 基线糖尿病病程4.2±2.8年,平均HbA1c 7.5±0.5%(58±5.3 mmol/mol),BMI 34.3±6.8 kg/m²,二甲双胍剂量1944±204 mg/天。
- 67%有高血压病史,72%有高脂血症病史,6.5%有心脏病发作或卒中病史。
- 应用GRADE入选标准后NHANES队列平均年龄57.9岁,平均HbA1c 7.4%(57 mmol/mol),BMI 33.2 kg/m²,病程4.2±2.5年,7.2%有心血管疾病史。
临床怎么用
- GRADE结果有助于指导二甲双胍单药控制不佳的2型糖尿病患者加用第二种降糖药的选择。
- GRADE队列特征与真实世界NHANES人群相似,研究结论可能具有较好外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) is a 36-center unmasked, parallel treatment group, randomized controlled trial evaluating four diabetes medications added to metformin in people with type 2 diabetes (T2DM). We report baseline characteristics and compare GRADE participants to a National Health and Nutrition Examination Survey (NHANES) cohort. RESEARCH DESIGN AND METHODS: Participants were age ≥30 years at the time of diagnosis, with duration of T2DM <10 years, HbA1c 6.8-8.5% (51-69 mmol/mol), prescribed metformin monotherapy, and randomized to glimepiride, sitagliptin, liraglutide, or insulin glargine. RESULTS: At baseline, GRADE's 5,047 randomized participants were 57.2 ± 10.0 years of age, 63.6% male, with racial/ethnic breakdown of 65.7% white, 19.8% African American, 3.6% Asian, 2.7% Native American, 7.6% other or unknown, and 18.4% Hispanic/Latino. Duration of diabetes was 4.2 ± 2.8 years, with mean HbA1c of 7.5 ± 0.5% (58 ± 5.3 mmol/mol), BMI of 34.3 ± 6.8 kg/m2, and metformin dose of 1,944 ± 204 mg/day. Among the cohort, 67% reported a history of hypertension, 72% a history of hyperlipidemia, and 6.5% a history of heart attack or stroke. Applying GRADE inclusion criteria to NHANES indicates enrollment of a representative cohort with T2DM on metformin monotherapy (NHANES cohort average age, 57.9 years; mean HbA1c, 7.4% [57 mmol/mol]; BMI, 33.2 kg/m2; duration, 4.2 ± 2.5 years; and 7.2% with a history of cardiovascular disease). CONCLUSIONS: The GRADE cohort represents patients with T2DM treated with metformin requiring a second diabetes medication. GRADE will inform decisions about the clinical effectiveness of the addition of four classes of diabetes medications to metformin.
引用
- Wexler DJ, Krause-Steinrauf H, Crandall JP, et al. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2019. PMID: 31391203. doi:10.2337/dc19-0901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。